^
    24h
    Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    Cotellic (cobimetinib) • pelcitoclax (APG-1252)
    1d
    VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial (clinicaltrials.gov)
    P2, N=48, Recruiting, Beijing 302 Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • idarubicin hydrochloride
    1d
    Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P2, N=120, Recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • aclarubicin
    1d
    Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML (clinicaltrials.gov)
    P2, N=42, Completed, University of Colorado, Denver | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Dec 2025
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax) • azacitidine
    2d
    Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Northside Hospital, Inc.
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 deletion
    |
    Venclexta (venetoclax) • decitabine • Niktimvo (axatilimab-csfr)
    2d
    Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia (clinicaltrials.gov)
    P2, N=204, Recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    2d
    A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    Venclexta (venetoclax) • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    3d
    Targeting BCL-xL in Myeloid Malignancies: From Inhibitors to PROTAC. (PubMed, J Cell Mol Med)
    A first milestone was the discovery of ABT-263 (navitoclax), a dual BCL-2/BCL-xL inhibitor. Building on this achievement, the development of venetoclax, a highly selective BCL-2 inhibitor, marked a major breakthrough, demonstrating potent pro-apoptotic activity and clinical efficacy in several leukaemia subtypes. Despite these advances, the design of inhibitors of BCL-2 family members remains challenging, largely due to the structural characteristics of the BH3-binding groove, which is both shallow and hydrophobic, complicating the identification of molecules with optimal binding affinity and selectivity. PROTACs targeting BCL-xL may represent a promising future strategy, potentially overcoming the intrinsic limitations of small molecule inhibitors.
    Review • Journal
    |
    MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
    |
    Venclexta (venetoclax) • navitoclax (ABT 263)
    3d
    BGB-11417-105: A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=246, Recruiting, BeOne Medicines | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • carfilzomib • pomalidomide • sonrotoclax (BGB-11417)
    5d
    Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML (clinicaltrials.gov)
    P1/2, N=52, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • MECOM (MDS1 And EVI1 Complex Locus)
    |
    pelcitoclax (APG-1252)
    5d
    A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    sonrotoclax (BGB-11417) • catadegbrutinib (BGB-16673)